Healthcare Analysts Weigh In on Immunocore Holdings and Exact Sciences

Analysts have conflicting sentiments on Immunocore Holdings (IMCR) and Exact Sciences (EXAS). Mizuho Securities maintained a Hold rating on IMCR with a price target of $36.00, while BTIG reiterated a Buy rating on EXAS with a price target of $60.00. IMCR has a Moderate Buy consensus rating with a $56.78 price target, while EXAS has a Strong Buy consensus rating with a $61.63 price target.

Analysts have presented differing views on the future prospects of Immunocore Holdings (IMCR) and Exact Sciences (EXAS). Mizuho Securities maintained a Hold rating on IMCR with a price target of $36.00, while BTIG reiterated a Buy rating on EXAS with a price target of $60.00. Despite these varying opinions, both companies have shown notable progress in their respective sectors.

Immunocore Holdings (IMCR)

Immunocore's Q2 2025 results indicate a robust financial performance. Net product sales for KIMMTRAK®, its flagship TCR bispecific therapy, surged to $98.0 million, a 30% year-over-year increase [1]. This growth was driven by a 15% rise in U.S. sales and a 71% year-over-year jump in Europe. Despite rising R&D and SG&A expenses, Immunocore's net loss narrowed to $10.3 million in Q2 2025, reflecting the company's ability to manage costs effectively. With $883 million in cash reserves, Immunocore has the financial flexibility to fund its pipeline without immediate dilution risks [1].

The company's strategic expansion includes the TEBE-AM and PRISM-MEL-301 trials targeting broader melanoma indications and PRAME-expressing cancers. These trials, along with global partnerships, underscore Immunocore's commitment to diversifying its pipeline and expanding its global reach [1]. The T-cell therapy market is projected to grow at a 12% CAGR, reaching $20.9 billion by 2035, providing a significant growth opportunity for Immunocore [1].

Exact Sciences (EXAS)

Exact Sciences reported a strong Q2 2025 performance, with an earnings per share (EPS) of -$0.01, which was a 92.31% positive surprise. Revenue for the quarter also surpassed expectations, totaling $811.1 million compared to the forecasted $773.8 million [2]. Despite these positive results, several analysts have adjusted their price targets for the company. Bernstein SocGen lowered its target to $60, citing surprising developments in the blood-based CRC screening program, while BTIG maintained a Buy rating with a price target of $60.00 [2].

The company’s revenue exceeded guidance and beat consensus expectations by 5%, driven largely by the commercial turnaround for core Cologuard. Management raised guidance across the board while maintaining some conservatism for the second half of the year and announced a program to achieve $150 million in annual cost savings by 2026 [2]. While currently unprofitable, analysts expect the company to turn profitable this year.

Conclusion

The contrasting analyst ratings and price targets for Immunocore and Exact Sciences reflect the differing views on the companies' growth prospects and market potential. While Immunocore's strategic expansion and strong financial performance position it as a leader in T-cell therapy, Exact Sciences' robust Q2 results and leading role in colorectal cancer screening have analysts divided on its future prospects. Investors should carefully consider these factors when evaluating their investment strategies.

References:
[1] https://www.ainvest.com/news/immunocore-2025-q2-performance-strategic-momentum-cell-therapy-biotech-innovator-path-immuno-oncology-leadership-2508/
[2] https://www.investing.com/news/analyst-ratings/btig-lowers-exact-sciences-stock-price-target-to-60-on-freenome-deal-93CH-4184639